Atherosclerosis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Atherosclerosis – Drugs In Development, 2023’, provides an overview of the Atherosclerosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
- The report reviews pipeline therapeutics for Atherosclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Atherosclerosis therapeutics and enlists all their major and minor projects
- The report assesses Atherosclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Atherosclerosis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
ABIONYX Pharma SAAcclivity Technologies Inc
Afimmune Biopharma Ltd
Amgen Inc
Amytrx Therapeutics Inc
Annexin Pharmaceuticals AB
AptaBio Therapeutics Inc
Artery Therapeutics Inc
Asdera LLC
AstraZeneca Plc
Auxagen Inc
Beijing Inno Medicine Co Ltd
Beren Therapeutics PBC
BioMe Inc
Bitterroot Bio Inc
Boehringer Ingelheim International GmbH
Cantargia AB
Celloram Inc
Centeer BioTherapeutics Ltd Co
Center of Molecular Immunology
Chinese Academy of Medical Sciences and Peking Union Medical College
Chroma Medicine Inc
Civi Biopharma Inc
CohBar Inc
Corvidane
CRISPR Therapeutics AG
Cyclarity Therapeutics Inc
Daiichi Sankyo Co Ltd
Dalian Wista Pharmaceutical Co Ltd
Drug Farm Inc
Elgia Therapeutics Inc
Eli Lilly and Co
HCW Biologics Inc
Helmholtz Center Munich German Research Center for Health and Environment GmbH
iMetabolic Biopharma Corp
Innolife Co Ltd
Inotrem SA
Ionis Pharmaceuticals Inc
Iproteos SL
Johns Hopkins University
Keystone Bio Inc
KineMed Inc
Kyttaro Ltd
Leiden University
LipimetiX Development Inc
Ludwig-Maximilians-University Munich
Max Biopharma Inc
Merck & Co Inc
MetiMedi Pharmaceuticals Co Ltd
NewAmsterdam Pharma Company NV
Notable Labs Ltd
Novartis AG
Novo Nordisk AS
NYU Langone Health System
Omeros Corp
Oregon State University
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Pharmahungary Group
PharmGen Science Inc
Polysan
PrimeGen Global Inc
Qingdao University
Rebus Holdings Inc
Repair Biotechnologies Inc
Sanford Burnham Prebys Medical Discovery Institute
Sanofi
Sema4 OpCo Inc
Serene LLC
Shanghai Henlius Biotech Inc
Shin Poong Pharm Co Ltd
Signablok Inc
Silence Therapeutics Plc
Sun Yat-sen University
SUNY Downstate Medical Center
SynAct Pharma AB
Takeda Pharmaceutical Co Ltd
Technical University of Munich
Tel Aviv University
The Scripps Research Institute
Tiara Pharmaceuticals Inc
Tourmaline Sub Inc
U.S. National Institutes of Health
University Hospital Freiburg
University Hospital Geneva
University of California San Diego
University of Hong Kong
University of North Carolina at Chapel Hill
University of Oxford
Vanderbilt University
Vasocure Therapeutics
VasoRx Inc
Vaxil Bio Therapeutics Ltd
Verve Therapeutics Inc
Wake Forest University
XBiotech Inc
Zehna Therapeutics LLC
ZyVersa Therapeutics Inc